Health ❯ Medicine ❯ Neurology

Alzheimer's Disease

Clinical Trials Drug Development Treatment Treatment Approaches Biomarkers Therapeutic Approaches Early Onset and Genetic Risk Treatment Methods Tau Pathology Neural Connectivity Lithium Deficiency Hormone Replacement Therapy Genetics Carnosic Acid Drug Research FDA Approval Levetiracetam Cognitive Function Association with Air Pollution Tau Phosphorylation Prevention and Risk Factors Symptom Delay Alpha-Amyrin Drug Therapy GLP-1 Drugs Immune Response Early Warning Signs Amyloid Pathology Liraglutide Cognitive Enhancement Cognitive Decline Treatments Lecanemab Early Detection of Alzheimer's Early Symptomatic Treatment Donanemab Prevention Antibody Therapy Experimental Treatments Research Estrogen and Memory Loss Risk Factors Intranasal Insulin Genetic Predisposition Amyloid Beta Nanoparticles Lithium Treatment Protein Changes Protein Networks Effects of Yoga on Alzheimer's Amyloid-beta Peptides

Biogen's Tau Drug Cuts Brain Tau but Misses Dose‑Response Goal

Data suggesting that lowering tau can slow Alzheimer’s progression have prompted Biogen to plan a pivotal Phase 3 in 2027.

Human‑Safe Drug Restores Neuronal DNA Repair in Mouse Model of Alzheimer’s

Copper Compound Restores Brain Clearance Pump and Cuts Alzheimer’s Proteins in Mice

Brain Estrogen Loss Alters Hippocampal Matrix and Impairs Memory in Older Female Mice

Lithium Chloride Rewires Alzheimer’s-Linked Pathways in Cell Study

Anti-Seizure Drug Levetiracetam Blocks Early Alzheimer’s Protein Production, Study Finds

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Engineered Nanoparticles Restore Blood–Brain Barrier and Clear Amyloid in Alzheimer’s Mice

Nanoparticles Restore Brain Barrier, Reverse Alzheimer’s Signs in Mice

Inhaled CBD Dampens Brain Inflammation in Alzheimer’s Mouse Model

Lancet Series Calls for Health-System Overhaul to Deliver New Alzheimer’s Blood Tests and Antibody Drugs

Alzheimer’s Study Ties Familial SORL1 Variant to Fewer, Weaker Brain Exosomes

Engineered Antibody Transport Vehicle Boosts Alzheimer’s Antibody Delivery to Mouse Brain

UCSF Validates GPCR ADGRG1’s Role in Clearing Alzheimer’s Plaques, Paving Way for New Therapies

Wake Forest Plans Expanded Trials After PET Study Validates Intranasal Insulin Delivery

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials